Chengdu Kanghong Pharmaceutical Group (002773.SZ): Kanghong's compound eye injection has received approval for supplementary clinical trial application.

Chengdu Kanghong Pharmaceutical Group (002773.SZ) announced that its wholly-owned subsidiary Chengdu Kanghong Biotechnology Co., Ltd. (referred to as "Kanghong Biotechnology") has received the "Drug Clinical Trial Supplementary Application Approval Notice" for Kangbixip Eye Injection issued by the National Medical Products Administration. Kangbixip Eye Injection is a class 1 biopharmaceutical innovator developed independently by the company's wholly-owned subsidiary Kanghong Biotechnology with complete intellectual property rights. This product can effectively bind with VEGF in blood vessels and tissues, blocking the signal transduction that promotes angiogenesis mediated by VEGF. This exploration of high-dose Kangbixip Eye Injection in clinical applications is expected to improve patient compliance and reduce the medical burden.